Definium Therapeutics, Inc.
DFTX
Clasificación en acciones
#3543
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Precio por acción
$35.52
Última sincronización: 2026-10-21
Capitalización bursátil
$4.77B
Cambio (1 día)
1.24%
Cambio (1 año)
185.79%
País
US
Comercio Definium Therapeutics, Inc. (DFTX)
Categoría
Healthcare
Historial del precio de la acción de Definium Therapeutics, Inc. (DFTX)
Precio más alto de cierre: $35.12 el 2026-10-01
Precio más bajo de cierre: $4.81 el 2016-11-01
Precio más bajo de cierre: $4.81 el 2016-11-01
Historial del precio de la acción de Definium Therapeutics, Inc. desde 2016 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | 98.99% |
| 2025 | 74.98% |
| 2024 | 107.98% |
| 2023 | 34.70% |
| 2022 | -89.90% |
| 2021 | -40.72% |
| 2020 | 7,946.66% |
| 2019 | -31.09% |
| 2018 | -81.58% |
| 2017 | -37.50% |
| 2016 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.73 | -3.85% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
